Next Article in Journal
Eastern Canadian Colorectal Cancer Consensus Conference: Application of New Modalities of Staging and Treatment of Gastrointestinal Cancers
Previous Article in Journal
Fertility Risk Discussions in Young Patients Diagnosed with Colorectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 3
10.3747/co.19.1064
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

by
R. Van der Jagt
1,*,
P. Laneuville
2,
D. MacDonald
3,
D. Stewart
4,
A. Christofides
5 and
L.H. Sehn
6
1
University of Ottawa, Ottawa, ON, Canada
2
McGill University, Montreal, QC, Canada
3
Dalhousie University, Halifax, NS, Canada
4
University of Calgary, Calgary, AB, Canada
5
New Evidence, Toronto, ON, Canada
6
University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(3), 160-168; https://doi.org/10.3747/co.19.1064
Submission received: 9 March 2012 / Revised: 11 April 2012 / Accepted: 7 May 2012 / Published: 1 June 2012

Abstract

Despite the success of standard treatments in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), patients are often unable to tolerate aggressive regimens, and they require effective alternatives. Bendamustine is a bifunctional alkylator with unique properties that significantly distinguish it from other agents in its class. In untreated CLL, bendamustine has demonstrated rates of response and progression-free survival (PFS) that are superior to those with chlorambucil, with an acceptable toxicity profile. In the relapsed setting, combination treatment with bendamustine–rituximab (BR) has demonstrated promising activity in high-risk patients such as those refractory to fludarabine or alkylating agents. In untreated patients with indolent NHL and mantle cell lymphoma, BR has demonstrated a PFS significantly longer than that achieved with R-CHOP (rituximab–cyclophosphamide–doxorubicin–vincristine–prednisone), with significantly reduced toxicity. In the relapsed setting, BR has demonstrated rates of response and PFS superior to those with fludarabine–rituximab, with comparable toxicity. In the United States and Europe, bendamustine has been approved for the treatment of CLL and indolent NHL; its approval in Canada is pending and eagerly awaited. Once available, bendamustine will benefit many Canadian patients with NHL and CLL.
Keywords: bendamustine; chronic lymphocytic leukemia; non-Hodgkin lymphoma; follicular lymphoma bendamustine; chronic lymphocytic leukemia; non-Hodgkin lymphoma; follicular lymphoma

Share and Cite

MDPI and ACS Style

Van der Jagt, R.; Laneuville, P.; MacDonald, D.; Stewart, D.; Christofides, A.; Sehn, L.H. A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Curr. Oncol. 2012, 19, 160-168. https://doi.org/10.3747/co.19.1064

AMA Style

Van der Jagt R, Laneuville P, MacDonald D, Stewart D, Christofides A, Sehn LH. A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Current Oncology. 2012; 19(3):160-168. https://doi.org/10.3747/co.19.1064

Chicago/Turabian Style

Van der Jagt, R., P. Laneuville, D. MacDonald, D. Stewart, A. Christofides, and L.H. Sehn. 2012. "A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma" Current Oncology 19, no. 3: 160-168. https://doi.org/10.3747/co.19.1064

APA Style

Van der Jagt, R., Laneuville, P., MacDonald, D., Stewart, D., Christofides, A., & Sehn, L. H. (2012). A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Current Oncology, 19(3), 160-168. https://doi.org/10.3747/co.19.1064

Article Metrics

Back to TopTop